PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2827721

Thyroid function in trophoblastic disease.

M Lemon·B R Bevan·T C Li·G W Pennington
View original source ↗Export metadata ↓

Abstract

Human chorionic gonadotrophin (hCG) levels and thyroid function were monitored in 44 patients receiving chemotherapy for treatment of trophoblastic disease. We observed a strong correlation between hCG and thyroid stimulating hormone (TSH) concentrations measured by radioimmunoassay, and this appears to be due to cross-reactivity between hCG and the anti-TSH antibody used. The concentration of thyroid hormones was little affected by the raised levels of TSH or hCG, except when the concentration of the latter rose to high levels, usually above 100,000 i.u./l. The possible mechanisms of thyroid homeostasis in trophoblastic disease are considered.

Explore related subjects

Antineoplastic Combined Chemotherapy ProtocolsChorionic GonadotropinFemaleHumansPregnancyThyroid GlandThyrotropinThyroxineTriiodothyronineTrophoblastic NeoplasmsUterine NeoplasmsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Lemon, B R Bevan, T C Li, G W Pennington. 1987. Thyroid function in trophoblastic disease.. https://doi.org/10.1111/j.1471-0528.1987.tb02294.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.

PURPOSE: The feasibility of adjuvant cisplatin, methotrexate and vinblastine chemotherapy was evaluated in Taiwanese patients with invasive transitional cell carcinoma at high risk for recurrence. MATERIALS AND METHODS: We assigned 56 patients with high risk transitional cell carcinoma (vascular or lymphatic invasion in the primary tumor, poorly differentiated stage P2, P3, P4 or N+ and M0) to receive adjuvant chemotherapy after radical urological surgery. The chemotherapy consisted of 40 mg./m.2 methotrexate and 4 mg./m.2 vinblastine on days 1 and 8, and 100 mg./m.2 cisplatin on day 2 given in 6 courses at 21-day intervals. RESULTS: Median followup was 44 months. An average of 4.63 cycles of chemotherapy was administered. The median actual survival was 44 months, and the 1 and 3-year survival probabilities were 92% and 50%, respectively. The median disease-free survival was 15.5 months, and the 1 and 3-year disease-free survival probabilities were 66% and 28%, respectively. Only 5 (9%) and 1 (2%) patients had grades 3 and 4 leukopenia, respectively, and none died of sepsis. CONCLUSIONS: The use of adjuvant cisplatin, methotrexate and vinblastine chemotherapy in patients with invasive transitional cell carcinoma at high risk for recurrence is feasible with tolerable toxicity but randomized controlled trials will be required to assess the benefit.

Antineoplastic Combined Chemotherapy Protocols↗